News and Information-Learn About Hepatitis, Liver Cirrhosis, and Others
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Hope for Damaged Heart Muscle

In lab study, re-engineered cells show promise for cardiac treatment

MONDAY, July 20 (HealthDay News) -- Researchers have genetically engineered cells that help form scar tissue after a heart attack into a type of cell that does just the opposite -- repairs damage to the heart muscle, a new study in mice shows.

The research team from the Mayo Clinic in Rochester, Minn., reprogrammed fibroblasts -- cells that play a role in scarring -- into becoming induced pluripotent stem (iPS) cells, which are stem cells that have been converted from adult cells.

Advertisement
Related Stories
 border=
Lung Transplant Outcome Might Hinge on Hospital Location
Hepatitis A Vaccine Pays Off for Kids: Study
Eye Condition May Alter Corneal Transplant Results
Related Videos
 border=
Blood Cleaner
High Tech Liver Surgery
Living Longer With Liver Cancer
Related Slides
 border=
Hepatitis
Liver Cirrhosis
Liver Transplant
Related Encyclopedia
 border=
Arteriohepatic Dysplasia
Fatty Liver
Hemochromatosis


The iPS cells were then transplanted into damaged mouse hearts, where they engrafted after two weeks. After four weeks, the mice hearts had improved structure and function, according to the study authors.

The iPS cells improved heart muscle performance, halted progression of structural damage to the already damaged heart and regenerated tissue at the site of damage, the researchers said.

"This study establishes the real potential for using iPS cells in cardiac treatment," study author Dr. Timothy Nelson said in a Mayo Clinic news release. "Bioengineered fibroblasts acquired the capacity to repair and regenerate infarcted hearts."

This study, which is reported online in the journal Circulation, was the first time iPS cells were used to repair heart tissue. Previous studies have investigated using iPS cells to treat Parkinson's disease, sickle cell anemia and hemophilia A.

Because iPS cells are derived from the patient, there is no risk of rejection or need for anti-rejection drugs, the researchers noted.

The hope is to one day be able to use iPS cells to repair injuries, helping to alleviate the demand for organ transplantation.

"This iPS innovation lays the groundwork for translational applications," senior study author Dr. Andre Terzic, Mayo Clinic physician-scientist, said in the same news release.

More information

The American Heart Association has more on heart attacks.

-- Jennifer Thomas

SOURCE: Mayo Clinic, news release, July 20, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 7/20/2009



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Aug 1, 2010
Home
Search
Powered By HealthLine
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: